Pharma behemoth Eli Lilly (NYSE: LLY) posted better-than-expected fourth-quarter results ahead of the opening bell this morning. Specifically, the drugmaker topped Factset's consensus revenue estimate for the three-month period by a healthy 3.38% and Wall Street's non-GAAP earnings-per-share forecast by a striking 13.8%. Those are exceptional quarterly results by any measure.
Nonetheless, Lilly's shares don't come across as a screaming buy, despite the company's industry-leading levels of top- and bottom-line growth in the most recent quarter. Here's why investors may want to stick to the sidelines with this blue-chip pharmaceutical stock right now.
Image source: Getty Images.
Source Fool.com